Orbit develop and apply innovative drug discovery platforms defined by a unique peptide display engine that deliver novel, functional, biologically relevant peptide therapeutic leads. The Orbit peptide display engine is uniquely able to address cell-based targets and thereby screen targets in relevant contexts. Peptide leads are key starting points for the development of peptide, peptidomimetic and small molecule therapeutics as well as bioconjugates for cell targeting and cargo delivery. Founded in late 2015 as a spin-out from Oxford University based on the work of Professors Graham Ogg and Terry Rabbitts. We have a pipeline of novel targets in in-house programmes and we work in collaboration with others in industry and academia to make our technology as accessible as possible.